Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA)
CUSIP: G9TY5A101
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Class A Ordinary Shares, par value $0.0001 per share
- Shares outstanding
- 108,236,654
- Total 13F shares
- 44,873,374
- Share change
- +3,639,604
- Total reported value
- $235,135,504
- Put/Call ratio
- 3439%
- Price per share
- $5.24
- Number of holders
- 74
- Value change
- +$20,833,671
- Number of buys
- 44
- Number of sells
- 30
Quarterly Holders Quick Answers
What is CUSIP G9TY5A101?
CUSIP G9TY5A101 identifies ZURA - Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP G9TY5A101:
Top shareholders of ZURA - Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Athanor Capital |
3/4/5
|
10%+ Owner |
11%
|
11,581,402
|
$46,209,793 | — | 29 Dec 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13D/G
13F
|
Company |
8.6%
|
5,567,001
|
$29,171,085 | $0 | 31 Dec 2025 | |
| BARCLAYS PLC |
3/4/5
13F
|
10%+ Owner · Company |
0%
from 13F
|
2,340,240
|
$24,349,729 | — | 09 Jan 2023 | |
| VR Adviser, LLC |
13F
|
Company |
4.3%
|
4,631,216
|
$20,053,165 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
13D/G
|
Company |
7.5%
from 13D/G
|
4,624,199
|
$20,022,782 | — | 30 Sep 2025 | |
| GREAT POINT PARTNERS LLC |
13D/G
13F
|
Company |
5.2%
|
3,815,930
|
$19,995,473 | $0 | 31 Dec 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.8%
|
3,045,444
|
$13,186,773 | — | 30 Sep 2025 | |
| PFIZER INC |
13F
13D/G
3/4/5
|
Company · Pfizer Inc. 13-5315170 · 10%+ Owner |
4.6%
from 13D/G
|
2,970,022
|
$12,860,195 | — | 30 Sep 2025 | |
| BRAIDWELL LP |
13F
|
Company |
2.3%
|
2,472,806
|
$10,707,250 | — | 30 Sep 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
2%
|
2,132,322
|
$9,232,953 | — | 30 Sep 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
9.9%
|
6,353,353
|
$8,322,892 | -$888,073 | 30 Jun 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.4%
|
1,560,000
|
$6,754,800 | — | 30 Sep 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
1.2%
|
1,274,351
|
$5,517,940 | — | 30 Sep 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
— |
4.9%
|
3,217,503
|
$4,633,204 | $0 | 31 Dec 2024 | |
| Someit Sidhu |
3/4/5
|
Director |
—
mixed-class rows
|
1,479,956
mixed-class rows
|
$4,338,550 | — | 21 May 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.76%
|
824,078
|
$3,568,258 | — | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.67%
|
726,328
|
$3,145,000 | — | 30 Sep 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.67%
|
720,452
|
$3,119,557 | — | 30 Sep 2025 | |
| ADAR1 Capital Management, LLC |
13D/G
13F
|
Company |
3.2%
|
2,077,251
|
$2,991,241 | $0 | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.54%
|
589,700
|
$2,553,401 | — | 30 Sep 2025 | |
| Amit Munshi |
3/4/5
|
Director |
—
mixed-class rows
|
828,384
mixed-class rows
|
$2,433,212 | — | 21 May 2025 | |
| FMR LLC |
13F
|
Company |
0.49%
|
531,286
|
$2,300,468 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.48%
|
517,144
|
$2,239,234 | — | 30 Sep 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.46%
|
500,000
|
$2,165,000 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.37%
|
405,304
|
$1,755,635 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.34%
|
365,674
|
$1,583,368 | — | 30 Sep 2025 | |
| Verender S. Badial |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
820,619
mixed-class rows
|
$1,412,827 | — | 08 May 2025 | |
| UBS Group AG |
13F
|
Company |
0.28%
|
305,329
|
$1,322,075 | — | 30 Sep 2025 | |
| Atika Capital Management LLC |
13F
|
Company |
0.25%
|
276,000
|
$1,195,080 | — | 30 Sep 2025 | |
| Deep Track Capital, LP |
13F
13D/G
|
Company |
0.4%
from 13D/G
|
259,014
|
$1,121,531 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.24%
|
255,400
|
$1,105,882 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.23%
|
247,747
|
$1,072,745 | — | 30 Sep 2025 | |
| Michael Howell |
3/4/5
|
Chief Scientific Officer and Head of Translational Science |
—
mixed-class rows
|
529,904
mixed-class rows
|
$1,063,813 | — | 18 Jun 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.2%
|
211,882
|
$917,448 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.19%
|
209,426
|
$906,814 | — | 30 Sep 2025 | |
| Christopher Cabell |
3/4/5
|
CMO & Head of R&D |
—
class O/S missing
|
162,060
|
$648,240 | — | 18 May 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.13%
|
144,363
|
$625,092 | — | 30 Sep 2025 | |
| Arnout Ploos van Amstel |
3/4/5
|
Director |
—
mixed-class rows
|
151,000
mixed-class rows
|
$620,000 | — | 21 May 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.13%
|
136,303
|
$590,192 | — | 30 Sep 2025 | |
| Alberta Investment Management Corp |
13F
|
Company |
0.12%
|
133,200
|
$576,756 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.11%
|
119,100
|
$515,703 | — | 30 Sep 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.11%
|
117,995
|
$510,918 | — | 30 Sep 2025 | |
| DLD Asset Management, LP |
13F
|
Company |
0.09%
|
100,000
|
$433,000 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.08%
|
86,437
|
$374,272 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.08%
|
81,723
|
$353,860 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.07%
|
80,528
|
$348,686 | — | 30 Sep 2025 | |
| RBF Capital, LLC |
13F
|
Company |
0.07%
|
80,000
|
$346,400 | — | 30 Sep 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.07%
|
76,609
|
$331,717 | — | 30 Sep 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.06%
|
65,900
|
$285,000 | — | 30 Sep 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.05%
|
49,360
|
$213,729 | — | 30 Sep 2025 |
Institutional Holders of Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA) as of Q4 2025
As of 31 Dec 2025,
Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA) was held by
74 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
44,873,374 shares.
The largest 10 holders included
SUVRETTA CAPITAL MANAGEMENT, LLC, VR ADVISER, LLC, JPMORGAN CHASE & CO, GREAT POINT PARTNERS LLC, BRAIDWELL LP, Pfizer Inc, ADAGE CAPITAL PARTNERS GP, L.L.C., Affinity Asset Advisors, LLC, ARMISTICE CAPITAL, LLC, and MORGAN STANLEY.
This page lists
74
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
65
Q4 2025 holders
74
Holder diff
9
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.